About: TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction. TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. Prolonged exposure of TRAIL-sensitive leukemia cell line HL60 cells to recombinant TRAIL or to cytostatic agents, cytarabine and idarubicin, resulted in the establishment of resistant subclones with distinct phenotypes. The TRAIL resistant subclones had decreased expression of TRAIL and TNFa death receptors, impaired activation of caspases 8 and 10 in response to TRAIL and TNFa and dysregulated expression of several apoptosis regulators. TRAIL resistant HL60 showed two phenotypes with different expression of CD14, osteoprotegerin, and several apoptosis regulators and were resistant to TNFa, suggesting disruption of the extrinsic apoptotic pathway. The concurrently derived cytarabine and idarubicin-resistant HL60 subclones remained sensitive to TRAIL-induced apoptosis. We identified distinct pathways for the development of HL60 leukemia cell resistance to apoptosis induction. (en)
Title	TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine (en)
skos:prefLabel	TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFa but not to idarubicin and cytarabine (en)
skos:notation	RIV/68378050:_____/09:00334040!RIV10-MSM-68378050
http://linked.open...avai/riv/aktivita	P S Z
http://linked.open...avai/riv/aktivity	P(1M0506), P(LC06044), P(NR8317), S, Z(AV0Z50520514), Z(MSM0021620806), Z(MSM0021620808)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Anděra, Ladislav
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav molekulární genetiky AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	346656
http://linked.open...ai/riv/idVysledku	RIV/68378050:_____/09:00334040
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	TRAIL resistance; leukemia; therapy (en)
http://linked.open.../riv/klicoveSlovo	leukemia therapy TRAIL resistance
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[7C5FF7CF4D5E]
http://linked.open...i/riv/nazevZdroje	Blood Cells Molecules and Diseases
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...vavai/riv/projekt	Regulatory mechanisms of growth and apoptosis of primary leukemia progenitor/stem cells. Center of Molecular and Cellular Immunology Center for Experimental Hematology
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	42
http://linked.open...iv/tvurceVysledku	Anděra, Ladislav Nečas, E. Živný, J. Čermák, J. Klener, P. jr. Leahomschi, S. Molinsky, J. Simonova, T. Doležalová, L. Gašová, Z.
http://linked.open...ain/vavai/riv/wos	000262347900014
http://linked.open...n/vavai/riv/zamer	Molekulárně genetické a buněčné základy klíčových biologických procesů: genová exprese, onkogeneze, replikace virů, imunita a vývoj organismů Molekulární biologie a patologie buňky za normy a u vybraných klinicky závažných patologických procesů Molekulárně biologické, genetické a epigenetické aspekty vzniku a rozvoje modelových tumorů dospělého věku. Význam pro epidemiologii, časnou diagnostiku a léčbu
issn	1079-9796
number of pages	8 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 35 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software